semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 41-year-old man and a known case of Acromegaly who underwent transsphenoidal surgery 4 months ago. He came to the clinic for the follow up lab studies after his primary resection surgery. His lab study shows the IGF-1 level of 4.5 ULN adjusted by sex and age. His random GH level is 4 ug/L. The recent brain MRI confirmed the residual pituitary tumor. His past medical history is only significant for acromegaly due to pituitary adenoma and the recent surgery. After his surgery he takes only vitamin D and multivitamins.

Clinical trial eligibility criteria: eligible ages (years): 18.0-100.0,  CNS Tumors Meningioma Esthesioneuroblastoma Hemangioblastoma Medulloblastoma Paraganglioma Pituitary Adenoma ≥ 18 years of age Diagnosis of meningioma based on pathology reports and suspected recurrence or residual disease based on standard-of-care MRI Additionally, patients with other somatostatin receptor 2 positive brain tumors, including esthesioneuroblastoma, hemangioblastoma, medulloblastoma, paraganglioma, pituitary adenoma, and SSTR-positive systemic cancers metastatic to the brain will be considered for the purposes of obtaining feasibility data As the investigator's institution, PET/MRI scanner utilizes a 3 Tesla (T) magnet, patients who may be ineligible to undergo 3T MRI but may undergo 1.5 Tesla (T) MRI, will undergo a 1.5T MRI as per clinical standard-of-care and a Ga68-DOTATATE PET/CT with the PET portion to be fused with the 1.5T MRI utilizing fusion software  Contraindications to gadolinium-based contrast agent History of allergic reaction to Gallium-68-DOTATATE Pregnancy
Patient description: The patient is a 41-year-old man and a known case of Acromegaly who underwent transsphenoidal surgery 4 months ago. He came to the clinic for the follow up lab studies after his primary resection surgery. His lab study shows the IGF-1 level of 4.5 ULN adjusted by sex and age. His random GH level is 4 ug/L. The recent brain MRI confirmed the residual pituitary tumor. His past medical history is only significant for acromegaly due to pituitary adenoma and the recent surgery. After his surgery he takes only vitamin D and multivitamins.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Arthropathy of Knee Any patient scheduled for primary total knee replacement arthroplasty  Diabetic patients 2. Rheumatoid arthritis patients 3. Patients on regular steroid therapy 4. Patients refused to be enrolled in the study
Patient description: The patient is a 41-year-old man and a known case of Acromegaly who underwent transsphenoidal surgery 4 months ago. He came to the clinic for the follow up lab studies after his primary resection surgery. His lab study shows the IGF-1 level of 4.5 ULN adjusted by sex and age. His random GH level is 4 ug/L. The recent brain MRI confirmed the residual pituitary tumor. His past medical history is only significant for acromegaly due to pituitary adenoma and the recent surgery. After his surgery he takes only vitamin D and multivitamins.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Glaucoma are all patients with glaucoma who have been listed for implantation of micro-invasive glaucoma surgical devices, with or without cataract surgery  Advanced glaucoma (as defined as cup-disc ratio ≥ 0.9 and/or a visual field defect within central 10˚ of fixation) ; diagnosis of glaucoma other than POAG and PACG (including uveitic, neovascular, traumatic glaucoma or glaucoma secondary to raised episcleral venous pressure); prior incisional glaucoma surgery or cataract surgery; presence of scarring, prior surgery or other conjunctival pathologies in the target quadrant; presence of vitreous in the anterior chamber; presence of intraocular silicone oil; clinically significant inflammation or infection in the study eye within 30 days before the pre-operative visit; known or suspected allergy or sensitivity to drugs required for the surgery (including anaesthesia) or any of the device components (eg. porcine products and glutaraldehyde); and any corneal, choroidal, retinal, orbital disease which may interfere with MIGS device implantation
Patient description: The patient is a 41-year-old man and a known case of Acromegaly who underwent transsphenoidal surgery 4 months ago. He came to the clinic for the follow up lab studies after his primary resection surgery. His lab study shows the IGF-1 level of 4.5 ULN adjusted by sex and age. His random GH level is 4 ug/L. The recent brain MRI confirmed the residual pituitary tumor. His past medical history is only significant for acromegaly due to pituitary adenoma and the recent surgery. After his surgery he takes only vitamin D and multivitamins.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Prolactinoma Prolactin-Producing Pituitary Tumor At least 18 years of age A history of signs and symptoms compatible with the diagnosis prolactinoma New, recent (PRolaCT-1) or known diagnosis of hyperprolactinaemia, defined as a prolactin level 2 times the local laboratory maximum. At the time of randomization hyperprolactinaemia is still present, or was present < 12 months before (PRolaCT-2 and PRolaCT-3) No clear alternative explanation for hyperprolactinaemia, e.g. medication use Presence of a clearly identifiable (persisting) pituitary mass on MRI not invading the cavernous sinus and having an optimal chance to be completely resected (generally adenomas with a maximum diameter nog exceeding 25mm). A representative MRI at the time of randomization is required, this MRI should generally not be older than 12 months in PRolaCT-3 and 2 months in PRolaCT-1 and PRolaCT-2 Competent and able to fill in questionnaires One of the following, dividing patients in to our three RCTs PRolaCT-1: no prior treatment for prolactinoma PRolaCT-2: treatment with a dopamine agonist for 4-6 months; or PRolaCT-3: treatment with a dopamine agonist for at least 2 years  Contraindication for one of the treatment modalities, e.g. severe side effect of cabergoline, contraindications to surgery, or a clear indication for surgical resection Pregnancy at the time of randomization Clinical acromegaly Prior pituitary gland surgery or radiotherapy to the pituitary gland area Severe renal failure (eGFR <30 ml/min) Insufficient understanding of the Dutch or English language Other medical conditions that to the opinion of the physician are not compatible with in a trial. Patients eligible for participation in one of the RCTs, but do not consent to randomisation or in whom there is a clear patient or physician preference for either DA treatment or surgery, are considered for participation in PRolaCT-O
Patient description: The patient is a 41-year-old man and a known case of Acromegaly who underwent transsphenoidal surgery 4 months ago. He came to the clinic for the follow up lab studies after his primary resection surgery. His lab study shows the IGF-1 level of 4.5 ULN adjusted by sex and age. His random GH level is 4 ug/L. The recent brain MRI confirmed the residual pituitary tumor. His past medical history is only significant for acromegaly due to pituitary adenoma and the recent surgery. After his surgery he takes only vitamin D and multivitamins.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Brain Neoplasms Glioma (LGG, HGG and recurrent HGG) Planned treatment for WHO grade II-IV diffuse glioma Adult patients (>18 years) Planned tissue sampling for histopathological diagnosis KPS >60 (able to care for self) Brain Metastasis Indication of surgery or stereotactic radiosurgery for 1-4 brain metastases Planned surgery: Suspicion of brain metastasis or known diagnosis Stereotactic surgery: Known primary cancer Adult patients (>18 years) Estimated survival at least 3 months after  (Glioma and Brain Metastasis) Pacemakers or defibrillators not compatible with 3T MRI No ability to obtain informed consent (e.g. due to severe dysphasia or cognitive deficits) Pregnancy (pregnancy test for all women in fertile age when doubt about possible pregnancy exist) Breastfeeding Weight > 120 kg
Patient description: The patient is a 41-year-old man and a known case of Acromegaly who underwent transsphenoidal surgery 4 months ago. He came to the clinic for the follow up lab studies after his primary resection surgery. His lab study shows the IGF-1 level of 4.5 ULN adjusted by sex and age. His random GH level is 4 ug/L. The recent brain MRI confirmed the residual pituitary tumor. His past medical history is only significant for acromegaly due to pituitary adenoma and the recent surgery. After his surgery he takes only vitamin D and multivitamins.

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  Hypothyroidism Thyroid Disease Euthyroid Thyroid Gland Thyroid Hormones Participants who have a diagnosis of primary hypothyroidism made ≥ 12 months before study entry (Visit 1) Be on continuous thyroid replacement therapy with synthetic T4 for primary hypothyroidism for at least 12 months immediately prior to the Screening Visit (Visit 1) Be on a stable FDA-approved daily dose of synthetic T4 for a minimum of 3 months prior to the Screening Visit (Visit 1). Must enter the study on the same stable dose Have euthyroid status indicated by at least 1 documented TSH value within normal reference range (0.45 4.12 mIU/L, inclusive) at a minimum of 6 weeks and maximum of 12 months prior to the Screening Visit (Visit 1). Also have a confirmed TSH value within the normal reference range drawn at the Screening Visit (Visit 1) Male and female participants willing to minimize the risk of inducing pregnancy for the duration of the clinical study and follow-up period (35 days after last dose of study intervention)  Any clinical condition or previous surgery that might affect the absorption, distribution, biotransformation, or excretion of Armour Thyroid or synthetic T4 History of alcohol or other substance abuse within the previous 5 years Known or suspected allergy or intolerance to any ingredients of Armour Thyroid, including its excipients, levothyroxine (T4), other thyroid replacement medications, or pork products Have received active treatment with an investigational drug within 30 days or 5 half lives, whichever is longer, of Screening Visit (Visit 1) Current enrollment in an investigational drug or device study or participation in such a study within 60 days of entry into this study
Patient description: The patient is a 41-year-old man and a known case of Acromegaly who underwent transsphenoidal surgery 4 months ago. He came to the clinic for the follow up lab studies after his primary resection surgery. His lab study shows the IGF-1 level of 4.5 ULN adjusted by sex and age. His random GH level is 4 ug/L. The recent brain MRI confirmed the residual pituitary tumor. His past medical history is only significant for acromegaly due to pituitary adenoma and the recent surgery. After his surgery he takes only vitamin D and multivitamins.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Thyroid Neoplasms Genetic Susceptibility Radiation Exposure Diganosis of thyroid cancer during the followup or selected as a control matched on gender, date of birth and age at skin hemangioma diagnosis  No available adress Refusal
Patient description: The patient is a 41-year-old man and a known case of Acromegaly who underwent transsphenoidal surgery 4 months ago. He came to the clinic for the follow up lab studies after his primary resection surgery. His lab study shows the IGF-1 level of 4.5 ULN adjusted by sex and age. His random GH level is 4 ug/L. The recent brain MRI confirmed the residual pituitary tumor. His past medical history is only significant for acromegaly due to pituitary adenoma and the recent surgery. After his surgery he takes only vitamin D and multivitamins.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Vitamin D Deficiency Women British African-Caribbean Self-reported Having African ancestral origin and migrated via the Caribbean islands, or having at least one parent with African ancestral origin that migrated via the Caribbean Living in England for >2 months Aged 18-35 or >55 years No significant health issues Pre-menopausal (regular menstrual periods) or Post-menopausal (menstrual periods stopped for longer than 12 consecutive months) BMI 18-30kg/m2  Women in perimenopause or menopause Pregnant or planning pregnancy during study period Hypercalcaemia (>2.5mmol/L) assessed and excluded at baseline Currently receiving treatment for medical conditions that are likely to affect vitamin D metabolism (osteoporosis, hormone replacement therapy, anti-estrogens treatment, antiepileptic drugs and breast cancer treatment) Regular use of sun beds Having a sun holiday one month prior to commencing study or plans for a sun holiday for more than 4 weeks within the study period Women who take vitamin D or calcium supplements (or multivitamin supplements that contain these vitamins) If potential participant agrees to stop supplement use to join the study, a wash-out period of 8 weeks prior to commencing the study is acceptable Living in England for less than 2 months
Patient description: The patient is a 41-year-old man and a known case of Acromegaly who underwent transsphenoidal surgery 4 months ago. He came to the clinic for the follow up lab studies after his primary resection surgery. His lab study shows the IGF-1 level of 4.5 ULN adjusted by sex and age. His random GH level is 4 ug/L. The recent brain MRI confirmed the residual pituitary tumor. His past medical history is only significant for acromegaly due to pituitary adenoma and the recent surgery. After his surgery he takes only vitamin D and multivitamins.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Platelet Dysfunction Due to Drugs between 18 and 74 years of age, 2. have stable coronary artery disease, already on DAPT with aspirin and clopidogrel for at least 6 months, 3. not on any physician-prescribed medications or complementary/alternative therapies  presence of active internal bleeding or history of bleeding diathesis or clinical findings associated with an increased risk of bleeding, 2. history of ischemic or hemorrhagic stroke, transient ischemic attack, intracranial neoplasm, arteriovenous malformation, or aneurysm, 3. history of clinical and/or hemodynamic instability, 4. within 1 month of placement of a bare-metal stent, 5. within 30 days of coronary artery bypass graft surgery or PCI without a stent placed, 6. planned coronary revascularization, 7. treatment with fibrin-specific fibrinolytic therapy <24 h or non-fibrin-specific fibrinolytic therapy <48 h, 8. use of an oral anticoagulation agent or international normalized ratio >1.5, 9. body weight <60 kg, 10. age >75 years, 11. hemoglobin <10 g/dL, 12. platelet count <100×106/μL, 13. creatinine >2 mg/dL, 14. hepatic enzymes >2.5 times the upper limit of normal, 15. pregnancy and/or lactation
Patient description: The patient is a 41-year-old man and a known case of Acromegaly who underwent transsphenoidal surgery 4 months ago. He came to the clinic for the follow up lab studies after his primary resection surgery. His lab study shows the IGF-1 level of 4.5 ULN adjusted by sex and age. His random GH level is 4 ug/L. The recent brain MRI confirmed the residual pituitary tumor. His past medical history is only significant for acromegaly due to pituitary adenoma and the recent surgery. After his surgery he takes only vitamin D and multivitamins.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Pituitary Tumor Pituitary Adenoma Pituitary Macroadenoma Patients with an established diagnosis of PitNET with a Knosp grade of 3 or 4 who are scheduled to undergo TSS WHO performance status 0-2 Signed written informed consent  Medical or psychiatric conditions that compromise the patient's ability to give informed consent Pregnant or lactating women. Documentation of a negative pregnancy test must be available for woman of childbearing potential. Woman of childbearing potential are pre menopausal women with intact reproductive organs and women less than two years after menopause History of infusion reactions to bevacizumab or other monoclonal antibody therapies Inadequately controlled hypertension with or without current antihypertensive medication Within 6 months prior to myocardial infarction, TIA, CVA, pulmonary embolism, uncontrolled chronic hepatic failure, unstable angina pectoris
Patient description: The patient is a 41-year-old man and a known case of Acromegaly who underwent transsphenoidal surgery 4 months ago. He came to the clinic for the follow up lab studies after his primary resection surgery. His lab study shows the IGF-1 level of 4.5 ULN adjusted by sex and age. His random GH level is 4 ug/L. The recent brain MRI confirmed the residual pituitary tumor. His past medical history is only significant for acromegaly due to pituitary adenoma and the recent surgery. After his surgery he takes only vitamin D and multivitamins.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Renal Transplant Recipients Non-functioning Pituitary Adenoma Patients with a renal transplant (RTX) OR patients with Non functioning pituitary adenomas (NFPA) Able to read and speak Norwegian Have access to a Smart-phone or tablet Have their own secure access device (BankID)  N/A
Patient description: The patient is a 41-year-old man and a known case of Acromegaly who underwent transsphenoidal surgery 4 months ago. He came to the clinic for the follow up lab studies after his primary resection surgery. His lab study shows the IGF-1 level of 4.5 ULN adjusted by sex and age. His random GH level is 4 ug/L. The recent brain MRI confirmed the residual pituitary tumor. His past medical history is only significant for acromegaly due to pituitary adenoma and the recent surgery. After his surgery he takes only vitamin D and multivitamins.

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Helminthiasis Helminth Infection The included volunteer is a researcher within parasitology with focus on Trichuris trichiura and Trichiura suis. He planned to infect himself under medical supervision. This was his third self-infection with Trichuris. The only clinical criterion for his in the study was that he was healthy  N/A
Patient description: The patient is a 41-year-old man and a known case of Acromegaly who underwent transsphenoidal surgery 4 months ago. He came to the clinic for the follow up lab studies after his primary resection surgery. His lab study shows the IGF-1 level of 4.5 ULN adjusted by sex and age. His random GH level is 4 ug/L. The recent brain MRI confirmed the residual pituitary tumor. His past medical history is only significant for acromegaly due to pituitary adenoma and the recent surgery. After his surgery he takes only vitamin D and multivitamins.

Clinical trial eligibility criteria: eligible ages (years): 13.0-60.0,  Psoriasis minimum age 13 years maximum age 60 years both males and females affected with mild, moderate and severe psoriasis  hypertension cardiovascular disorders pregnancy lactation renal failure liver failure hypersensitivity to drug
Patient description: The patient is a 41-year-old man and a known case of Acromegaly who underwent transsphenoidal surgery 4 months ago. He came to the clinic for the follow up lab studies after his primary resection surgery. His lab study shows the IGF-1 level of 4.5 ULN adjusted by sex and age. His random GH level is 4 ug/L. The recent brain MRI confirmed the residual pituitary tumor. His past medical history is only significant for acromegaly due to pituitary adenoma and the recent surgery. After his surgery he takes only vitamin D and multivitamins.

Clinical trial eligibility criteria: eligible ages (years): 18.0-99.0,  Stroke, Ischemic Stroke Hemorrhagic For ischemic stroke  Age > 18-year-old Ischemic stroke diagnosed on clinical presentation and cerebral imaging (CT or MRI imaging) inferior to 6 hours from stroke onset Initial NIHSS score > 0 at the time of clinical examination Patients with multimodal imaging either through MRI or CT perfusion and supra-aortic vessels and intra-cerebral vessels (Willis circle) imaging <0 Procedure of signed consent in situation of emergency : consent of the patient if he has the possibility to sign or his representative if he is present For hemorragic stroke  Age > 18 year-old Hemorrhagic stroke diagnosed on clinical presentation and cerebral imaging (CT or MRI imaging)  Not affiliated to social security Patient under legal protection or deprived of liberty by a judicial or administrative decision Patient whose follow-up will be impossible Prior stroke GROUP FOR  Patients with TIA and a negative cerebral CT or MRI GROUP FOR  Cerebral hemorrhage related to subarachnoid hemorrhage Post-traumatic hemorrhage Hemorrhagic transformation in patients with ischemic stroke GROUP FOR  Contraindication MRI
Patient description: The patient is a 41-year-old man and a known case of Acromegaly who underwent transsphenoidal surgery 4 months ago. He came to the clinic for the follow up lab studies after his primary resection surgery. His lab study shows the IGF-1 level of 4.5 ULN adjusted by sex and age. His random GH level is 4 ug/L. The recent brain MRI confirmed the residual pituitary tumor. His past medical history is only significant for acromegaly due to pituitary adenoma and the recent surgery. After his surgery he takes only vitamin D and multivitamins.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Cavernous Sinus Invasion by Pituitary Adenoma Patients undergoing preoperative brain MR for pituitary adenoma  Patients who have any type of bioimplant activated by mechanical, electronic, or magnetic means (e.g., cochlear implants, pacemakers, neurostimulators, biostimulates, electronic infusion pumps, etc), because such devices may be displaced or malfunction Patients who are pregnant or breast feeding; urine pregnancy test will be performed on women of child bearing potential Poor MRI image quality due to artifacts
Patient description: The patient is a 41-year-old man and a known case of Acromegaly who underwent transsphenoidal surgery 4 months ago. He came to the clinic for the follow up lab studies after his primary resection surgery. His lab study shows the IGF-1 level of 4.5 ULN adjusted by sex and age. His random GH level is 4 ug/L. The recent brain MRI confirmed the residual pituitary tumor. His past medical history is only significant for acromegaly due to pituitary adenoma and the recent surgery. After his surgery he takes only vitamin D and multivitamins.

Clinical trial eligibility criteria: eligible ages (years): 18.0-90.0,  AKI (Acute Kidney Injury) Due to Trauma 18 years of age or older 2. Scheduled to undergo CAG and/or PCI 3. Baseline estimated glomerular filtration rate (eGFR) of ≥20 and ≤60 mL/ min/1.73 m2 4. Serum creatinine > 1.5mg/dl 5. Obtaining a Cardiac catheterization. 6. HTN/Diabetes 7. Inpatient and outpatient  91 years of age or older 2. Serum creatinine < 1.5mg/dl 3. eGFR > 60ml/min 4. Pregnancy 5. Dialysis 6. Dye Allergy
Patient description: The patient is a 41-year-old man and a known case of Acromegaly who underwent transsphenoidal surgery 4 months ago. He came to the clinic for the follow up lab studies after his primary resection surgery. His lab study shows the IGF-1 level of 4.5 ULN adjusted by sex and age. His random GH level is 4 ug/L. The recent brain MRI confirmed the residual pituitary tumor. His past medical history is only significant for acromegaly due to pituitary adenoma and the recent surgery. After his surgery he takes only vitamin D and multivitamins.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Pituitary Adenoma volunteers macroadenomas at least 1 hormonal axis affected Karnofsky Perfomance Scale between 70-100 65 years approved by cardiologists  regular exercise habit acute pain in many part of the body additional neurologic condititons any rheumatological and immunologic conditions